Related Experiment Video
Updated: Jan 20, 2026

The Encapsulation of Cell-free Transcription and Translation Machinery in Vesicles for the Construction of Cellular Mimics
Published on: October 21, 2013
DUBbing Down Translation: The Functional Interaction of Deubiquitinases with the Translational Machinery
Bandish B Kapadia1, Ronald B Gartenhaus1,2
1University of Maryland School of Medicine, Baltimore, Maryland. rgartenhaus@som.umaryland.edu BKapadia@som.umaryland.edu.
Abstract:
Cancer cells revamp the regulatory processes that control translation to induce tumor-specific translational programs that can adapt to a hostile microenvironment as well as withstand anticancer therapeutics. Translational initiation has been established as a common downstream effector of numerous deregulated signaling pathways that together culminate in prooncogenic expression. Other mechanisms, including ribosomal stalling and stress granule assembly, also appear to be rewired in the malignant phenotype. Therefore, better understanding of the underlying perturbations driving oncogenic translation in the transformed state will provide innovative therapeutic opportunities. This review highlights deubiquitinating enzymes that are activated/dysregulated in hematologic malignancies, thereby altering the translational output and contributing to tumorigenesis.
Insights
Cancer cells alter protein translation for survival and therapy resistance. This review focuses on deubiquitinating enzymes driving these changes in blood cancers, offering new therapeutic targets.
Area of Science:
- Molecular Biology
- Oncology
- Biochemistry
Background:
- Cancer cells reprogram gene expression via translation control.
- Translational control is crucial for tumor adaptation and therapeutic resistance.
- Dysregulated translation contributes to malignant transformation.
Purpose of the Study:
- To review the role of deubiquitinating enzymes in cancer translation.
- To highlight deubiquitinating enzymes dysregulated in hematologic malignancies.
- To identify therapeutic opportunities targeting oncogenic translation.
Main Methods:
- Literature review of studies on translation regulation in cancer.
- Focus on deubiquitinating enzymes and their impact on protein synthesis.
- Analysis of alterations in hematologic malignancies.
Main Results:
- Deubiquitinating enzymes are frequently activated or dysregulated in blood cancers.
- These enzymes reprogram translational output to promote tumorigenesis.
- Altered translation contributes to cancer cell survival and drug resistance.
Conclusions:
- Targeting deubiquitinating enzymes offers a promising therapeutic strategy.
- Understanding oncogenic translation provides novel avenues for cancer treatment.
- Modulating translational control is key to overcoming therapeutic resistance.
More Related Videos
Related Concept Videos
10:28The Encapsulation of Cell-free Transcription and Translation Machinery in Vesicles for the Construction of Cellular Mimics
09:22Budding Yeast Protein Extraction and Purification for the Study of Function, Interactions, and Post-translational Modifications
Initiation of Translation
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
06:58Global Identification of Co-Translational Interaction Networks by Selective Ribosome Profiling
09:40Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes
11:19Isolation of Translating Ribosomes Containing Peptidyl-tRNAs for Functional and Structural Analyses

